Gene Therapy — Revision Notes

⚡ 30-Second Revision

Gene Therapy: Modifies genetic material to treat disease.
Types: Somatic (non-heritable, accepted), Germline (heritable, prohibited).
Vectors: Viral (AAV, Lentivirus, Adenovirus), Non-viral (Liposomes, Nanoparticles, Electroporation).
AAV: Low immunogenicity, infects dividing/non-dividing cells. Examples: Zolgensma (SMA), Luxturna (LCA).
Lentivirus: Integrates into host genome, stable expression. Used in CAR-T.
CAR-T Therapy: Genetically engineered T-cells to fight cancer (Leukemias, Lymphomas).
CRISPR-Cas9: Gene editing tool, precise DNA alteration. Distinct from gene therapy.
Indian Regulators: ICMR (guidelines), CDSCO (approvals).
Key Indian Policy: New Drugs and Clinical Trials Rules, 2019; National Biotechnology Development Strategy 2021–25.
Ethical Concerns: Germline prohibition, high cost, equitable access, informed consent.
Challenges: Safety (immunogenicity, off-target effects), Cost, Delivery efficiency.
Recent Approvals (2023-24): Casgevy (CRISPR for Sickle Cell/Thalassemia) in US/UK.
India's focus: Indigenous R&D, addressing genetic disease burden (Thalassemia, Sickle Cell).
Vyyuha Mnemonic VECTOR: V-Viral, E-Ethical, C-Cost, T-Target, O-Oversight, R-Regulation.
Vyyuha Mnemonic SAGE: S-Somatic, A-Applications, G-Germline, E-Ethics.

2-Minute Revision

Gene therapy is a revolutionary approach to treating diseases by correcting or modifying faulty genes. It involves delivering therapeutic genetic material into a patient's cells, primarily using modified viruses (vectors) like AAVs or Lentiviruses.

Key types include somatic gene therapy, which affects only the individual and is ethically accepted, and germline gene therapy, which alters reproductive cells and is globally prohibited due to heritable changes.

Applications span inherited disorders (e.g., SMA, LCA with Zolgensma, Luxturna), and cancers (e.g., CAR-T cell therapy for leukemias). While promising, significant challenges exist: the exorbitant cost, potential safety issues like immune responses or unintended genetic alterations, and the complexity of delivery.

In India, the ICMR and CDSCO regulate gene therapy research and clinical trials, guided by the New Drugs and Clinical Trials Rules, 2019, and the National Biotechnology Development Strategy 2021–25, aiming for indigenous development and equitable access despite the high costs and ethical dilemmas.

5-Minute Revision

Gene therapy is a cutting-edge biotechnology that corrects genetic defects at their source. It works by introducing, modifying, or removing genetic material in a patient's cells. The primary delivery vehicles are 'vectors,' often modified viruses (e.

g., Adeno-associated Viruses (AAVs), Lentiviruses) engineered to be harmless but efficient at transferring genes. Non-viral methods like liposomes and electroporation also exist, offering safety but generally lower efficiency.

The two main types are somatic gene therapy, which targets non-reproductive cells and is ethically permissible, and germline gene therapy, which affects reproductive cells and is globally prohibited due to concerns about altering the human gene pool.

Key applications include inherited genetic disorders like Spinal Muscular Atrophy (SMA) (treated by Zolgensma, an AAV therapy) and Leber Congenital Amaurosis (LCA) (treated by Luxturna, also AAV-based).

In cancer, CAR-T cell therapy genetically engineers a patient's T-cells to fight specific cancers (e.g., leukemias, lymphomas). Recent breakthroughs include CRISPR-based gene editing therapies like Casgevy for sickle cell disease and beta-thalassemia.

However, gene therapy faces substantial challenges: extremely high costs, potential safety risks (immunogenicity, off-target effects, insertional mutagenesis), and complex manufacturing. India's regulatory framework, overseen by ICMR and CDSCO (under the New Drugs and Clinical Trials Rules, 2019), aims to balance innovation with patient safety and ethical considerations.

The National Biotechnology Development Strategy 2021–25 emphasizes indigenous R&D to address India's significant burden of genetic disorders and improve affordability and access, which remain critical ethical and policy challenges.

Prelims Revision Notes

Focus on factual recall:

Definition: — Gene therapy = genetic material modification for disease treatment.
Types: — Somatic (non-heritable, accepted); Germline (heritable, prohibited globally).
Vectors: — Viral (AAV, Lentivirus, Adenovirus – know key features); Non-viral (Liposomes, Nanoparticles, Electroporation).
Key Therapies/Diseases: — Zolgensma (SMA, AAV); Luxturna (LCA, AAV); CAR-T (Leukemias/Lymphomas, Lentivirus); Casgevy (Sickle Cell/Thalassemia, CRISPR-based).
Regulatory Bodies (India): — ICMR (guidelines), CDSCO (approvals, New Drugs and Clinical Trials Rules, 2019).
Distinction: — Gene Therapy (gene addition/replacement) vs. Gene Editing (precise DNA alteration, e.g., CRISPR).
Ethical: — Germline prohibition is a key point. Cost is a major access barrier.

Mains Revision Notes

Develop analytical frameworks:

Introduction: — Define, state significance (curative potential).
Applications: — Inherited disorders, cancer, infectious diseases – provide specific examples.
Challenges: — Scientific (delivery, safety, long-term effects), Ethical (germline, informed consent, 'designer babies'), Economic (cost, access, affordability), Regulatory (balancing innovation/safety).
Indian Context: — Burden of genetic disorders, role of ICMR/CDSCO, National Biotechnology Development Strategy, 'Make in India' for indigenous R&D.
Policy Solutions: — Public funding, innovative financing, regulatory streamlining, ethical oversight, public awareness.
Conclusion: — Balanced perspective – immense promise with critical challenges requiring multi-stakeholder solutions for equitable access.

Vyyuha Quick Recall

Vyyuha Quick Recall Mnemonics:

VECTOR (for key aspects of Gene Therapy):

Viral & Non-viral (Delivery methods)
Ethical Concerns (Germline, Access)
Cost (High, Affordability)
Target Diseases (Inherited, Cancer)
Oversight (ICMR, CDSCO)
Regulation (New Drugs Rules, Guidelines)

SAGE (for types and ethical status):

Somatic (Gene Therapy)
Accepted (Ethically)
Germline (Gene Therapy)
Ethically Prohibited (Globally)

Infographic Suggestion: A visual representation (1200x630 px) depicting the 'VECTOR' mnemonic as a central graphic, with each letter branching out to a small icon and a brief explanatory phrase. For example, 'V' with a virus icon and 'Delivery Methods', 'E' with a scales of justice icon and 'Ethical Dilemmas'.

The 'SAGE' mnemonic could be a smaller inset comparing two figures, one with a 'no' sign for germline and one with a 'yes' for somatic. Alt text: 'Infographic summarizing key aspects of gene therapy using VECTOR and SAGE mnemonics for UPSC revision.

' Caption: 'Vyyuha Quick Recall: Mnemonics for Gene Therapy Essentials.